Quantification of topotecan and its metabolite N-desmethyltopotecan in human plasma, urine and faeces by high-performance liquid chromatographic methods

Journal of Chromatography B: Biomedical Sciences and Applications

Volumn 727, Issue 1-2, 1999, Pages 191-203

  Rosing, H ^a   Van Zomeren, D M ^a   Doyle, E ^b   Ten Bokkel Huinink, W W ^c   Schellens, J H M ^c   Bult, A ^d   Beijnen, J H ^a,c,d  

^a SLOTERVAART HOSPITAL   (Netherlands)

^b GLAXOSMITHKLINE   (United Kingdom)

^c ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

^d UTRECHT UNIVERSITY   (Netherlands)

Author keywords

N Desmethyltopotecan; Plasma; Topotecan; Urine

Indexed keywords

ANTINEOPLASTIC AGENT; TOPOTECAN;

ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG STRUCTURE; FECES ANALYSIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN TISSUE; OVARY CANCER; PRIORITY JOURNAL; QUANTITATIVE ASSAY; URINALYSIS;

ANTINEOPLASTIC AGENTS; CALIBRATION; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FECES; HUMANS; NEOPLASMS; REPRODUCIBILITY OF RESULTS; SPECTROMETRY, FLUORESCENCE; TOPOTECAN;

EID: 0032898870     PISSN: 13872273     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0378-4347(99)00078-X     Document Type: Article

References (14)

1. Hsiang Y-H., Liu L. Cancer Res. 48:1988;1722.
2. Hsaing Y-H., Liu L.F., Wall M.E., Wani M.C., Nicholas A.W., Manikuma G., Kirschenbaum S., Silber R., Potmesil M. Cancer Res. 49:1989;4385.
3. Underberg W.J.M., Goossen R.M.J., Smith B.R., Beijnen J.H. J. Pharm. Biomed. Anal. 8:1990;681.
4. Hertzberg R.P., Caranfa M.J., Holden K.G., Jakas D.R., Gallagher G., Mattern M.R., Mong S.M., Bartus J.O., Johnson R.K., Kingsbury W.D. J. Med. Chem. 32:1989;715.
5. ten Bokkel Huinink W.W., Gore M., Carmichael J., Gordon A., Hudson I., Broom C., Malfetano J., Scarabelli C., Davidson N., Spanczynski M., Bolis G., Malmstrom H., Coleman R., Fields S.Z., Heron J.F. J. Clin. Oncol. 15:1997;2177.
6. Herben V.M.M., ten Bokkel Huinink W.W., Beijnen J.H. Clin. Pharmacokinet. 31:1996;85.
7. Herben V.M.M., ten Bokkel Huinink W.W., Schot M.E., Hudson I., Beijnen J.H. Anti-Cancer Drugs. 9:1998;411.
8. Rosing H., Herben V.M.M., van Zomeren D.M., Hop E., Kettenes-van de Bosch J.J., ten Bokkel Huinink W.W., Beijnen J.H. Cancer Chemother. Pharmacol. 39:1997;498.
9. Beijnen J.H., Smith B.R., Keijer W.J., van Gijn R., ten Bokkel Huinink W.W., Vlasveld L.Th., Rodenhuis S., Underberg W.J.M. J. Pharm. Biomed. Anal. 8:1990;789.
10. Rosing H., Doyle E., Davies B.E., Beijnen J.H. J. Chromatogr. B. 668:1995;107.
11. Loos W.J., Stoter G., Verweij J., Schellens J.H.M. J. Chromatogr. B. 678:1996;309.
12. Warner D.L., Burke T.G. J. Chromatogr. B. 691:1997;161.
13. Lang J.R., Bolton S. J. Pharm. Biomed. Anal. 9:1991;435.
14. Shah V.P., Midha K.K., Dighe S., McGilveray I.J., Skelly J.P., Yacobi A., Layloff T., Viswanathan C.T., Cook C.E., McDowall R.D., Pittman K.A., Spector S. J. Pharm. Sci. 81:1992;309.